The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & Johnson
The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & Johnson
James Halley, The Motley FoolSun, February 22, 2026 at 1:05 PM UTC
0
Key Points -
Johnson & Johnson is a Dividend King.
Its size and breadth have allowed it to flourish despite the many changes in the healthcare space over the years.
Its total return over the past decade tops 200%.
10 stocks we like better than Johnson & Johnson ›
It's easy to get caught up in the latest hot stock, the newest trend, the flashiest sector. However, if you want steady, dependable income and a strong total return, buy Johnson & Johnson (NYSE: JNJ).
Yes, I know that's a boring statement, but if you want the closest thing to a guarantee other than death and taxes, the healthcare giant is the way to go. That's why I bought J&J shares years ago, and I don't ever plan on selling them.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Why do I love Johnson & Johnson's stock? Let me count the ways.
Reason No. 1: It has raised its dividend for 63 consecutive years
Let that sink in for a moment. The company is a Dividend King, one of a small group of companies that have raised their payouts for 50 or more consecutive years. It began raising its dividend in 1963, when John F. Kennedy was president. And amid all the upheaval since -- wars, economic downturns, and major changes in healthcare -- it has steadily kept boosting it.
Over the past decade, it has consistently provided single-digit percentage dividend increases, but those added up to a 73% total increase over that period. Last year, it raised its quarterly payout by 4.8% to $1.30 per share. At the stock's current price, that gives it a yield of 2.1%, almost double the S&P 500's average yield in December of 1.15%.
Moreover, the company's payout ratio of 46.3% shows it has plenty of room to continue those increases. While it paid out $12.4 billion in dividends in 2025, it produced about $20 billion in free cash flow.
A medical professional in a lab, taking notes as they stand in front of a microscope.
Image source: Getty Images.
Reason No. 2: Its total return outpaced the S&P 500 over the past year
Johnson & Johnson shares delivered a total return of more than 60% over the past year, about five times the return of the S&P 500. That's pretty good for a "boring" stock, though in most years, its total returns have been far more pedestrian.
The company did a lot right this year. Revenue rose 6% to $94.2 billion, while earnings per share (EPS) grew by 90.5% to $11.03. Adjusted EPS was $10.79, up 8.1%. In 2026, management is guiding for revenue in the $100 billion to $101 billion range, which would be a rise of 6.7% at the midpoint. It projects operational EPS to be between $11.43 and $11.63, an increase of 6.9% at the midpoint.
Advertisement
Reason No. 3: It isn't stuck in the past
Yes, the company has a 140-year history, but it also has its eyes firmly fixed on the future. It just announced plans to spend $1 billion on a next-generation cell manufacturing facility outside Philadelphia.
The new plant will support Johnson & Johnson's objective of making the majority of its advanced medicines within the U.S., which will allow it to meet domestic demand while reducing its tariff costs. The company said it plans an overall outlay of $55 billion in U.S. manufacturing, research and development (R&D), and technology through early 2029.
J&J consistently spends big on R&D -- $14.6 billion in 2025 alone -- and that pays off. Last year, it had 28 programs with $1 billion or more in sales. It also had 51 therapies approved in its innovative medicine division, and 15 new product launches in its medtech division.
Attributes like those may not be exciting, but they're why Johnson & Johnson is a stock I'll happily stick with for the long haul.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 22, 2026.
James Halley has positions in Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
Source: “AOL Money”
